/NVCR
NVCR Stock - NovoCure Limited
Healthcare|Medical - Instruments & SuppliesNASDAQ
$13.65-3.74%
$0.53 (-3.74%) • Jan 13
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.56
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.91
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+146.7%upside
Target: $33.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.51 – $13.79
TARGET (TP)$33.67
STOP LOSS$12.56
RISK/REWARD1:18.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.73
52W High$27.70
52W Low$10.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $605.22M | $509.34M | $537.84M | $535.03M | $494.37M |
| Gross Profit | $468.04M | $381.06M | $422.97M | $420.15M | $387.87M |
| Gross Margin | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% |
| Operating Income | $-170,496,000 | $-232,870,000 | $-89,523,000 | $-44,333,000 | $30.40M |
| Net Income | $-168,627,000 | $-207,043,000 | $-92,534,000 | $-58,351,000 | $19.81M |
| Net Margin | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% |
| EPS | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.20 |
Company Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NVCRBeat Rate
53%
Last 19 quarters
Avg Surprise
-116.0%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
+15.1%
$-0.45vs$-0.53
Q2 24
+16.3%
$-0.36vs$-0.43
Q3 24
+22.5%
$-0.31vs$-0.40
Q4 24
+17.6%
$-0.28vs$-0.34
Q1 25
-79.4%
$-0.61vs$-0.34
Q2 25
+34.0%
$-0.31vs$-0.47
Q3 25
+7.7%
$-0.36vs$-0.39
Q4 25
+21.4%
$-0.33vs$-0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.39 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Q3 2025 | Jul 24, 2025 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $-0.47 | $-0.31 | +34.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.34 | $-0.61 | -79.4% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $-0.40 | $-0.31 | +22.5% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.53 | $-0.45 | +15.1% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $-0.52 | $-0.46 | +11.5% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $-0.50 | $-0.54 | -8.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.36 | $-0.50 | -38.9% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.32 | $-0.36 | -12.5% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-0.30 | $-0.25 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $-0.14 | $-0.23 | -64.3% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $-0.17 | $-0.04 | +76.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.10 | $-0.25 | -150.0% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-0.06 | $-0.13 | -116.7% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-0.01 | $-0.14 | -1674.4% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | $-0.01 | $-0.04 | -300.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about NVCR
What is NVCR's current stock price?
NovoCure Limited (NVCR) is currently trading at $13.65 per share. The stock has moved -3.74% today.
What is the analyst price target for NVCR?
The average analyst price target for NVCR is $33.67, based on 1 analyst.
What sector is NovoCure Limited in?
NovoCure Limited operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is NVCR's market cap?
NovoCure Limited has a market capitalization of $1.53 billion, making it a small-cap company.
Does NVCR pay dividends?
No, NovoCure Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTA
Azenta, Inc.
$38.50
Mkt Cap: $1.8B
BLFS
BioLife Solutions, Inc.
$23.90
Mkt Cap: $1.2B
ESTA
Establishment Labs Holdings Inc.
$65.13
Mkt Cap: $1.9B
EVO
Evotec SE
$3.87
Mkt Cap: $1.4B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$22.04
Mkt Cap: $1.3B
NEOG
Neogen Corporation
$9.19
Mkt Cap: $2.0B
PLSE
Pulse Biosciences, Inc.
$14.15
Mkt Cap: $1.0B
STAA
STAAR Surgical Company
$21.13
Mkt Cap: $1.0B
TDOC
Teladoc Health, Inc.
$6.99
Mkt Cap: $1.2B
UPB
Upstream Bio, Inc.
$32.60
Mkt Cap: $1.8B
Explore stocks similar to NVCR for comparison